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Abstract: Electroencephalography (EEG) represents a widely established method for assessing al-
tered and typically developing brain function. However, systematic studies on EEG data quality, its
correlates, and consequences are scarce. To address this research gap, the current study focused on
the percentage of artifact-free segments after standard EEG pre-processing as a data quality index.
We analyzed participant-related and methodological influences, and validity by replicating landmark
EEG effects. Further, effects of data quality on spectral power analyses beyond participant-related
characteristics were explored. EEG data from a multicenter ADHD-cohort (age range 6 to 45 years),
and a non-ADHD school-age control group were analyzed (ntotal = 305). Resting-state data during
eyes open, and eyes closed conditions, and task-related data during a cued Continuous Performance
Task (CPT) were collected. After pre-processing, general linear models, and stepwise regression
models were fitted to the data. We found that EEG data quality was strongly related to demographic
characteristics, but not to methodological factors. We were able to replicate maturational, task,
and ADHD effects reported in the EEG literature, establishing a link with EEG-landmark effects.
Furthermore, we showed that poor data quality significantly increases spectral power beyond ef-
fects of maturation and symptom severity. Taken together, the current results indicate that with
a careful design and systematic quality control, informative large-scale multicenter trials charac-
terizing neurophysiological mechanisms in neurodevelopmental disorders across the lifespan are
feasible. Nevertheless, results are restricted to the limitations reported. Future work will clarify
predictive value.
Keywords: electroencephalography (EEG); data quality; attention-deficit/hyperactivity disorder
(ADHD); artifacts; multicenter study
1. Introduction
Electroencephalography (EEG) is a non-invasive method for assessing brain-electrical
activity on the scalp using a set number of electrodes [1,2]. It has been widely used in the
research fields of physiology, psychology, neuroscience, and cognitive science to explore
the neural dynamics and circuits related to typically developing and altered human infor-
mation processing and behavior [3]. The weak surface EEG signal measured on the scalp is
extremely susceptible to interferences during the process of signal collection. Significant
signal distortions due to contamination through participant-induced artifacts or experimen-
tal factors sometimes lead to unavailability of sufficient EEG data for subsequent analyses,
resulting in a lower reliability of study results [4]. To this end, a series of offline processing
methods exists that are applied to EEG data for extracting uncontaminated signals prior
to further analyses. However, there is little standardization, and pre-processing methods
vary substantially [5,6].
As the quality of the raw data crucially impacts the validity of analyses and interpre-
tation of scientific results obtained from EEG, assessments of data quality are essential.
Evaluating the quality of the raw EEG signals ensures that established standards are met,
and results are replicable [7]. Especially, when EEG data are recorded at multiple sites,
in developmental populations, and in patient samples prone to EEG artifacts, they are
characterized by a high degree of artifact contamination. For example, data from patients
with attention-deficit/hyperactivity disorder (ADHD) are often contaminated by move-
ment artifacts due to symptoms of hyperactivity. The assessment of developmental and/or
psychiatric populations is typically associated with various challenges, subsequently con-
tributing to lower EEG data quality: Children often have problems following instructions
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(e.g., not to move during the measurement, to pay attention to task instructions). Further,
study protocols typically include far shorter measurement durations for a higher level
of tolerance resulting in a lower number of data points available for final evaluations.
Additionally, measures to assess physiological artifacts (such as EOG electrodes for ocular
movement contamination) are often not implemented. From a data processing perspec-
tive, extracting uncontaminated signals from such EEG recordings represents a particular
challenge. However, those signal distortions might provide additional useful information
characterizing specific developmental and psychiatric populations. Data quality might be
systematically related to age or specific psychiatric symptom dimensions with a poten-
tial relevance for classification purpose. This aspect is often neglected and not explicitly
addressed in ongoing clinical trials using EEG.
Although the EEG represents an established method for assessing neuronal activity,
systematic explorations of signal contamination are rather scarce and existing reports of
data quality measures are often inconsistent. Typically, studies only indirectly address
data quality by reporting impedance cut-offs (such as < 20 kΩ at each electrode location)
or standard cut-off values for the least-acceptable absolute number of sweeps included per
participant for subsequent analyses [8–10]. Further studies calculated analytical indices
using complex models to explicitly assess EEG data quality [11,12]. However, previous re-
ports were mainly focusing on data quality of wearable dry-electrode devices or when EEG
and functional magnetic resonance imaging (fMRI) data were collected simultaneously [13].
Other recent work focused on online-monitoring of data quality for neurofeedback and
brain–computer interface (BCI) applications [14]. Due to this lack of direct assessment and
consistent reporting, study quality can often only be indirectly inferred from publications
on EEG data. The same refers to study-specific variables potentially influencing it [15,16].
Identifying and adequately addressing EEG signal distortions ensures reliability of
study results. Beyond this, replicating robust landmark effects of the EEG literature informs
about the validity of analyzed data. However, to date there is little published data on
such appropriate validation analyses representing replication analyses of robust landmark
effects typically reported in the EEG literature that establish a link with data quality. Only
few replication studies have been done so far. Nevertheless, they are urgently needed for
consolidation of results in the field of EEG research [17]. Thereby, several robust landmark
effects have been identified (we do not claim for a comprehensive review of all relevant
EEG landmark effects): (I) For example, in the literature on resting-state EEG activity age
effects of increasing fast oscillatory activity and decreasing slow oscillatory activity due
to brain maturational processes have been consistently reported [18–24]. (II) Furthermore,
a substantial amount of studies reported on alpha blocking after transition from resting
state eyes closed to eyes open or task-related conditions, indicating a decrease in alpha
activity primarily in occipital brain regions [25–29]. (III) For task-related inhibitory control
activity assessed via Go/NoGo-paradigms, previous studies showed a substantially higher
amplitude of the Go-P3 event-related potential (ERP) compared to the NoGo-P3, especially
at posterior brain regions (e.g., [30,31]). This effect indicates a substantially stronger
neurophysiological activity in response to Go- compared to NoGo-trials, with the latter
requiring the inhibition of unwanted motor responses. In general, cognitive ERPs represent
stimulus-locked time epochs in the EEG that can be related to distinct cognitive processes.
(IV) In addition, a recent meta-analysis summarized previous study results on earlier versus
later cognitive ERPs in ADHD compared to non-ADHD populations [32]. Results show
that for early ERPs ADHD patients present shorter Go-P100-latencies when compared to
non-ADHD. For later ERPs, individuals with ADHD showed smaller Cue-P300-amplitudes,
longer Go-P300-latencies, smaller NoGo-P300-amplitudes, longer NoGo-P300-latencies,
smaller contingent negative variation (CNV-) amplitudes, and smaller Pe-amplitudes.
These robust empirical features found in the field of EEG research provide a reliable
framework for testing validity of EEG data.
Differences in EEG data quality might exist between different groups assessed within
a study due to developmental aspects or psychiatric symptoms. However, these contami-
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nations possibly represent valid, characteristic information of those developmental and/or
psychiatric populations with a substantial marker value. Those EEG data quality differ-
ences between study populations might subsequently have an impact on between-group
differences in classical EEG- and ERP-analyses, and the biomarkers identified. Extensive
efforts were made in previous studies to follow standards, control for artifacts, and include
sufficient uncontaminated EEG signals for analyses also in clinical contexts: (a) Adequate
designs and homogeneous participant groups were selected, and (b) different techniques
and pre-processing methods ensured sufficient (largely) artifact-free EEG. Nevertheless,
systematic group differences or remaining subtle signal distortions might still affect the
analyzed data. Only a few studies so far have explicitly addressed and modelled systematic
effects of EEG signal contaminations/data quality on results obtained in subsequent analy-
ses of EEG/ERP data (e.g., on spectral power; e.g., [32,33]) to demonstrate and quantify
such effects experimentally. However, these studies are urgently needed to explore the
additional explanatory value of data quality besides developmental processes linked to
brain maturation and ADHD symptoms, and to establish a link between the quality of
assessed EEG data and results from planned EEG/ERP analyses.
Here, we present EEG data quality parameters from a recently conducted multicenter
project assessing children, adolescents, and adults with ADHD, as well as non-ADHD
children in school-age as control group to give insights into data quality, participant-related
and methodological variables influencing data quality, as well as possible validation
analyses to link data quality and replication of previous study results. Furthermore, we
evaluated the additional influence of data quality on results obtained from spectral power
analyses of resting EEG data beyond effects due to maturational processes and symptom
severity. We suggest deriving data quality indices after pre-processing of the raw data by
defining data quality as how much of the raw data assessed could actually be included in
the final analyses. We go beyond the absolute number of acceptable segments after data
pre-processing that was often taken as an index of data quality in previous work, and divide
it by the total number of segments assessed to get an idea of how much data are useable for
subsequent analyses (percentage of artifact-free segments). Within this study we assess how
demographic, participant-related clinical (age, ADHD symptom dimensions, medication
status), and methodological (type of measurement, pre-processing method, measurement
duration) variables influence EEG data quality. We further conduct validation analyses to
replicate robust landmark effects typically reported in the EEG literature. Additionally, we
relate data quality to results obtained in spectral power analyses from resting EEG data
exploring additional effects of data quality besides maturation and ADHD symptoms on
results.
2. Materials and Methods
2.1. Participants
Pseudonymized data of children, adolescents, and adults (6–45 years) with ADHD for
the present study were obtained from the ESCAlife project (ESCAschool, ESCAadol, and
ESCAlate trials), a multicenter study including 14 sites (involving Bochum/Hamm, Bonn,
Essen, Frankfurt, Göttingen, Homburg, Köln, Mainz, Mannheim, Marburg, Oldenburg,
Rostock, Tübingen, and Würzburg). Details regarding the study protocol, each age-trial,
and data acquisition have been published previously [34–37]. Within ESCApreschool
(3–6 years), no EEG data were collected. All studies were previously registered by the
German Trial Register (reference numbers: DRKS00008973, DRKS00008974, DRKS00008975,
at: https://www.drks.de/drks_web/). Ethics approval was provided by the local ethical
committees for each participating center, and written informed consent was obtained from
the child, adolescent or adult. Furthermore, written assent was obtained from parents or
guardians for participants below the age of 18 years. Exclusion criteria were: IQ < 80, diag-
nosis of pervasive developmental disorder, schizophrenia, bipolar disorder, severe depres-
sive episode, epilepsy, heart disease, current or planned intensive behavioral therapy for
ADHD or oppositional behavior on a weekly basis, for children with severe ADHD known
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non-response to all standard ADHD medication (methylphenidate, dexamphenidate, and
atomoxetine), psychotropic medication (other than for ADHD) or neuroleptic medication
(other than for the treatment of disturbance of impulse control), insufficient German lan-
guage and reading skills of parents. IQ < 80, and insufficient German language skills were
chosen as selection criteria as they were deemed relevant for participation in planned
study-assessment (filling out questionnaires or understanding test instructions) and thera-
peutic interventions. EEG data within the ESCAlife-study were included from participants
of the ESCAbrain-trial assessing the neurobiological underpinnings of ADHD, and the
potential predictive value of neuronal markers for non-pharmacological treatment options.
EEG data were assessed before (pre assessment) and after (post assessment) an intense,
non-pharmacological intervention involving behavioral therapy (BT) or neurofeedback
(NF) therapy. Finally, data from n = 184 ADHD children (age in years: M = 8.99, SD = 1.59),
n = 39 adolescents with ADHD (age in years: M = 14.13, SD = 1.52), and n = 57 ADHD
patients in adulthood (age in years: M = 29.39, SD = 6.73) were included in the current
analyses. Furthermore, only at Mannheim center, 25 non-ADHD controls without any
psychiatric disorder between the age of 6.00 and 11.11 years (non-ADHD controls) were
assessed (age in years: M = 8.63, SD = 1.47), and EEG data were collected at two time points.
Post assessments were done approximately 6 months after pre assessment. As the focus of
the trials was on longitudinal aspects and changes due to different evidence-based ADHD
interventions rather than on case-control comparisons, the study protocols did not include
non-ADHD controls. Due to limited resources, non-ADHD controls could only be added
for children, who form the largest and best studied age group regarding ADHD, although
we acknowledge that a fully factorial design with controls in each age group would have
been preferable.
2.2. Assessment of Demographic Information, and Clinical Characterization
Demographic information including age was assessed within an interview prior to
any treatment or measurement. For clinical characterization and assessment of ADHD
symptoms, several scales and interviews were used (see Appendix A).
2.3. EEG Data Acquisition
EEG data were acquired at each of the involved sites with NEUROPRAX or THER-
APRAX full-band DC-EEG amplifier systems (with a high input impedance >10 GΩ for
proprietary impedance control; neuroCare GmbH, Germany). Resting state data were
collected with patients first having their eyes open and then eyes closed, four minutes each.
The resting-state EEG was recorded using a 22-channel EEG cap (Brain Products, Gilching,
Germany), and a sampling rate of 256 Hz (DC−70 Hz). A cued Continuous Performance
Task (CPT) was used to probe preparatory and inhibitory neurophysiological activity
(see Appendix A, for a detailed description). The EEG while performing the cued CPT
(in ADHD children from ESCAschool/non-ADHD control children) or the Flanker-version
(for adolescents and adults from ESCAadol, and ESCAlate, respectively) was recorded
using a higher sampling rate of 512 Hz. Impedances were kept below 20 kΩ.
2.4. Data Preparation
EEG data were pre-processed using BrainVision Analyzer (Version 2.1) including the
following pre-processing steps for the raw EEG signal: Offline filtering using Butterworth
Zero Phase filters, a high-pass filter of 0.01 Hz (24 dB/oct), and a low-pass filter of 70 Hz
(24 dB/oct). Furthermore, a notch filter of 50 Hz was applied. At first, data were inspected
to reject the noisiest segments. Subsequently, for correction of ocular blinks and eye
movements, an independent component analysis (ICA) was conducted based on a case-
wise visual inspection. Then, data were re-referenced to the average, and segmented
(division in equal sized components of 2.048 s for resting-state data). Further, an automatic
artifact-detection method was applied using an exclusion criterion of ±150 µV. For later
assessing the effects of different ocular correction methods, the same steps were repeated,
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but instead of using ICA decomposition, ocular blinks and eye movements were removed
by the procedure described by Gratton and colleagues [38].
To assess data quality after implementing all steps of pre-processing, the number of
good sweeps (< ±150 µV) was divided by the total number of sweeps assessed (percent-
age of artifact-free segments).
Regarding the validation analyses, for resting-state data, frequency band analyses
using fast-Fourier transformation (FFT) were carried out, with data being divided into beta
(12.5–30 Hz), alpha (7.5–12.5 Hz), theta (3.5–7.5 Hz), and delta (0.5–3.5 Hz) frequency bands,
focusing on the Fz, Cz, and Pz electrode locations. For task-related data assessed using the
cued CPT/Flanker-version of CPT, event-related potentials were extracted, focusing on the
P300 component, as well as the CNV. For further analyses of time effects in the resting EEG
eyes open and closed data, each data set was split in two time segments of equal size for
the first half and second half of the measurement. Datasets for validation analyses were
included with at least 20 segments per participant for resting data, and 10 segments for
CPT data per condition, respectively.
For ERP-validation analyses, amplitudes and latencies were calculated for each partic-
ipant for the Cue-P3 and the CNV components, as well as for Go- and NoGo-P3 compo-
nents [30,39–42]. Cue-P3 peaks were identified at electrode Pz within a time window of
300–750 ms after cue onset. The CNV component was quantified at electrode Cz, and the
most prominent statistical effects were expected within a time window of 1200–1650 ms
after cue onset. Go-P3 and NoGo-P3 were defined as the most positive peaks at around
280–600 ms at electrode Pz and FCz, respectively. Amplitudes for all ERP components, and
Cue-P3, Go-P3, and NoGo-P3 latencies were exported for further analysis.
2.5. Statistical Analyses
All statistical analyses were conducted using SPSS (version 24) and R software ver-
sion 3.5.1.
To explore the effects of demographic and clinical variables on data quality, stepwise
regression models were fitted to the data. To iteratively explore the influence of age,
ADHD symptoms (inattention, hyperactivity/impulsivity; z-standardized to compare
different scales used for children/adolescents, and adults, respectively), and medication
status, those variables were sequentially entered into the model as predictor variables
of interest. General linear models were used to analyze effects of condition, directly
comparing eyes open versus eyes closed resting conditions, versus CPT. Furthermore,
in paired-samples t-tests effects of different pre-processing methods, and measurement
duration were explored. For exploring site effects on data quality within the current
multicenter trial, again general linear models were fitted.
For validation analyses, correlational analyses (validation analysis I on age effects),
paired-samples t-tests (validation analysis II on alpha blocking in transition from eyes
closed to eyes open condition, and validation analysis III on CPT effects), as well as
independent samples t-tests (validation analysis IV on ERP differences between ADHD
and non-ADHD control children) were conducted. Validation analysis III and IV were
conducted in children only. As t-tests were conducted for replication purposes or on
different or only partly overlapping characteristics and datasets, no corrections for multiple
testing were implemented.
To explore the additional effects of data quality on EEG power spectra besides demo-
graphic characteristics, stepwise regression models were used.
3. Results
3.1. Participant Characteristics
Demographic information on included participants can be found in Table 1.
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Table 1. Demographic information.
































ADHD symptom scale ranges for non-ADHD controls, ADHD children from ESCAschool, and ADHD adolescents from ESCAadol: (0–3),
for ADHD adults from ESCAlate: (0–10).
3.2. Data Quality
3.2.1. Descriptive Statistics
The first research question aimed at exploring data quality in children, adolescents,
and adults with a diagnosis of ADHD, and school-age control children, and demographic,
patient-related (age, medication, patient status), as well as methodological (type of measure-
ment, pre-processing method, measurement duration) variables influencing data quality.
Table 2 shows the descriptive statistics for each condition, and all (age) groups, respectively.









73.35% (27.33) 75.80% (26.49) 69.92% (26.79)
ADHD children
from ESCAschool
41.28% (35.14) 37.27% (36.40) 30.96% (33.19)
ADHD adolescents
from ESCAadol
54.84% (38.84) 58.12% (38.29) 49.61% (38.81)
ADHD adults from
ESCAlate
57.78% (38.15) 66.61% (38.32) 64.63% (36.42)
Total 48.92% (36.87) 49.04% (38.95) 43.75% (37.42)
The pre assessment was carried out before the intense treatment schedule of the stepped-care treatment program
within the ECSAlife study.
3.2.2. Effects of Demographic and Clinical Information on Data Quality
A stepwise multiple regression was conducted to explore whether age, ADHD symp-
toms (inattention, hyperactivity/impulsivity), and medication status predict data quality.
For pre eyes open, the regression model revealed at step 1, age contributed significantly to
the regression model, F(1,224) = 5.41, p = 0.021), and accounted for 2.4% of the variation
in data quality. Introducing ADHD symptoms explained an additional 6.1%, and this
change in R2 was significant, F(3,222) = 6.84, p < 0.0001. This effect was primarily driven by
adding hyperactivity/impulsivity to the regression model, t = −2.62, p < 0.01 (inattention:
p > 0.05). Finally, the addition of medication explained an additional 0.6% of variation, but
the change in R2 was not significant, p > 0.05.
For pre eyes closed, the regression model revealed at step 1, age contributed signifi-
cantly to the regression model, F(1,223) = 15.52, p < 0.001, and accounted for 6.5% of the
variation in data quality. Introducing ADHD symptoms explained an additional 7.1%, and
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this change in R2 was significant, F(3,221) = 11.58, p < 0.0001. This effect was primarily
driven by adding hyperactivity/impulsivity to the regression model, t = −2.40, p = 0.017
(inattention: p > 0.05). Finally, the addition of medication explained an additional 2.0% of
variation, and this change in R2 was again significant, F(4,220) = 10.18, p < 0.0001. When
all independent variables were included at stage 3, a significant effect was revealed for
symptoms of inattention additionally, t = −2.19, p = 0.03.
When exploring pre CPT data quality, at step 1 in the regression model, a significant
effect of age was found, F(1,223) = 17.27, p < 0.001, accounting for 7.2% of variance. Adding
ADHD symptoms explained further 7.1% with a significant change in R2, F(3,221) = 12.29.
p < 0.001. Again, this effect was primarily driven by adding hyperactivity/impulsivity
to the regression model, t = −2.60, p = 0.010 (inattention: p > 0.05). Finally, the addition
of medication explained an additional 0.9% of variation, but the change in R2 was not
significant, p > 0.05.
Appendix B (Figures A1–A4) shows the associations between demographic variables
of interest and EEG data quality.
3.2.3. Effects of Condition and Further Methodological Variables on Data Quality
For analyzing the effects of condition (directly comparing eyes open versus eyes
closed versus CPT) across all participants, a general linear model was used. No significant
effect was obtained, indicating no differences in data quality for different measurement
conditions, p > 0.05.
Paired-samples t-tests were used to explore differences in data quality for different
pre-processing methods (semiautomatic ICA versus automatic correction according to
Gratton and Coles). Results show no significant differences for different ocular movement
correction methods, p > 0.05.
To analyze differences in data quality for measurement duration, paired-samples
t-tests were applied. No significant differences emerge for neither eyes open, nor eyes
closed condition at pre assessment, p > 0.05.
Descriptive statistics and detailed results can be found in Appendix C (Tables A1 and A2).
Results for the effects of study-site on data quality are also presented in Appendix C.
3.3. Validation Analyses
3.3.1. Validation Analysis I: Correlation between EEG Power Spectra and Age
Significant small to moderate negative correlations were obtained between age and
eyes open alpha activity, eyes open theta activity, and eyes open delta activity at Fz, Cz,
and Pz at pre assessment. For eyes closed, significant negative correlations were obtained
between age and alpha activity, theta activity, and delta activity at Fz, Cz, and Pz, re-
spectively. In addition, small negative correlations at Fz, and Pz electrode positions were
identified for beta activity. These results indicate that with increasing age, power in alpha,
theta, and delta bands decreases. Results across all participants are shown in Table 3.
Figure 1 presents absolute spectral power (log-transformed values are displayed for il-
lustrative purposes) in all frequency bands of interest for ADHD children, adolescents,
and adults, respectively. Appendix D (Figures A5–A10; Tables A3 and A4) shows the
associations between age and EEG spectral power in resting conditions across all partici-
pants. Further, for the purpose of comparison with previous literature [23], Appendix D
(Figures A11–A16) presents results from correlational analyses with only children and
adolescents included (<16 years of age), separately for ADHD groups and the non-ADHD
control children, as typically substantially higher associations are identified for younger
age groups and in non-ADHD control groups.
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Table 3. Correlations between age and fast-Fourier transformation (FFT) frequency band activity at pre assessment.
Eyes Open Eyes Closed
Electrode Location Fz Cz Pz Fz Cz Pz
beta (µV) × age (years) −0.130 −0.088 −0.058 −0.154 ◦ −0.125 −0.151 ◦
alpha (µV) × age (years) −0.265 *** −0.297 *** −0.155 ◦ −0.210 ** −0.299 *** −0.265 ***
theta (µV) × age (years) −0.461 *** −0.452 *** −0.324 ** −0.521 *** −0.471 *** −0.376 ***
delta (µV) × age (years] −0.387 *** −0.406 *** −0.415 *** −0.404 *** −0.449 *** −0.377 ***
Frequency band widths: beta (12.5–30 Hz), alpha (7.5–12.5 Hz), theta (3.5–7.5 Hz), and delta (0.5–3.5 Hz). Pearson product-moment
correlations are displayed. *** p ≤ 0.0001, ** p ≤ 0.001, ◦ p ≤ 0.05.
Figure 1. Averaged log10-transformed absolute spectral power in beta (12.5–30 Hz), alpha (7.5–12.5 Hz), theta (3.5–7.5 Hz),
and delta (0.5–3.5 Hz) frequency bands for ADHD children (black), adolescents (red), and young adults (blue), respectively.
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3.3.2. Validation Analysis II: Alpha Blocking in Transition from Eyes Closed to Eyes Open
Condition (Alpha Reactivity)
Paired samples t-Tests were conducted to compare FFT alpha activity in eyes open
versus eyes closed conditions at electrode locations Fz, Cz, and Pz, respectively. There
was a significant difference in alpha activity at all three electrode positions for eyes open
(Fz: M = 0.15, SD = 0.13; Cz: M = 0.19, SD = 0.19; Pz: M = 0.25, SD = 0.26) and eyes closed
(Fz: M = 0.27, SD = 0.22; Cz: M = 0.32, SD = 0.27; Pz: M = 0.68, SD = 0.75), t(208) = −8.549,
p < 0.001 at Fz, t(208) = −9.168, p < 0.001 at Cz, and t(208) = −9.783, p < 0.0001 at Pz,
respectively. These results indicate an increase in alpha activity at all three electrode
locations from eyes open to eyes closed condition (see also Figure 2).
Figure 2. Differences in alpha activity by condition at Fz (A), Cz (B), and Pz (C) electrode locations. Corresponding
topographical maps in the alpha frequency range of 7.5–12.5 Hz for eyes open, and eyes closed conditions, respectively (D).
*** p ≤ 0.0001, ** p ≤ 0.001, ◦ p ≤ 0.05.
Furthermore, a decrease in frontal beta, an increase in posterior beta, and an increase
in central and posterior theta activity from eyes open (M = 0.04, SD = 0.04, M = 0.03,
SD = 0.03, M = 0.33, SD = 0.30, M = 0.32, SD = 0.26) to eyes closed condition (M = 0.04, SD
= 0.02, M = 0.04, SD = 0.03, M = 0.38, SD = 0.31, M = 0.48, SD = 0.52) was obtained, t(208)
= 2.281, p = 0.024, t(208) = −4.203, p < 0.001, t(208) = −2.784, p = 0.006, t(208) = −5.832,
p < 0.001, respectively.
3.3.3. Validation Analysis III: CPT Task Effect: Comparison between Go- and Nogo-P3
Amplitude at Pz
Paired-samples t-tests were used to explore mean amplitude differences at Pz electrode
for Go- and NoGo-P3. Results show a significant difference between Go- and NoGo-P3
mean activity at posterior regions, with a substantially higher Go-P3 mean amplitude
(M = 20.00, SD = 6.65) compared to the NoGo-P3 component (M = 14.64, SD = 7.27),
t(128) = 9.402, p < 0.0001, see Figure 3.
3.3.4. Validation Analysis IV: ERP Differences between Children with ADHD and
Non-ADHD Controls
Descriptive statistics for ERP amplitudes and latencies of interest can be found in
Table 4.
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Figure 3. ERP Go- and NoGo-P3 components in children. (A) Stimulus-locked ERP wave shapes of the Go- (red) and NoGo-
P3 (black) components at electrode Pz. (B) Corresponding maps in the time range of the Go- and NoGo-P3 (280–600 ms).
*** p ≤ 0.0001, ◦ p ≤ 0.05.












122 −2.43 µV 4.59 µV 25 −3.07 µV 4.00 µV −0.548 0.585
Cue P3 amplitude 122 13.31 µV 5.43 µV 25 16.11 µV 5.04 µV 2.503 0.013
Cue P3 latency 122 506.96 118.76 ms 25 531.09 ms 108.26 ms 0.728 0.468
Go P3 amplitude 105 19.79 µV 6.26 µV 25 20.92 µV 7.99 µV 1.006 0.316
Go P3 latency 105 390.12 ms 99.23 ms 25 420.63 ms 102.01 ms 1.024 0.308
NoGo P3 amplitude 109 11.07 µV 8.12 µV 25 11.81 µV 6.76 µV 0.406 0.686
NoGo P3 latency 109 441.10 ms 76.13 ms 25 449.61 ms 69.39 ms 0.608 0.544
Peak definition: Cue-P3 at Pz within a time window of 300–750 ms after cue onset.
CNV at Cz, within a time window of 1200–1650 ms after cue onset. Go-P3 and NoGo-P3 at
around 280–600 ms at electrode Pz and FCz, respectively.
Comparing children with ADHD to non-ADHD control children in school-age, a
significant between-group difference was obtained for the Cue-P3 amplitude, t(145) = 2.37,
p = 0.019, indicating smaller Cue P3-amplitudes in ADHD children (M = 13.31, SD = 5.43)
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compared to non-ADHD ESCAschool-controls (M = 16.11, SD = 5.04; see Figure 4). No fur-
ther differences were obtained for other ERP components.
Figure 4. ERP Cue-P3 component for ADHD and non-ADHD control children. (A) Stimulus-locked ERP wave shapes
of the Cue-P3 component for ADHD patients (red), and non-ADHD control children (n = 24; black) at electrode Pz.
(B) Corresponding maps in the time range of the Cue-P3 (300–750 ms). * p ≤ 0.01, ◦ p ≤ 0.05.
3.4. The Additional Influence of Data Quality on Power Spectra (FFT) Results in Eyes Open and
Eyes Closed Resting Conditions
A stepwise multiple regression was conducted to explore whether age, ADHD symp-
toms (inattention, hyperactivity/impulsivity), and data quality predict FFT power spectra
from resting-state measurements.
For pre eyes open data quality, the models revealed an additional significant effect of
data quality in step 3 for alpha activity, as well as for beta activity at Fz, and Cz, respectively
(alpha: ∆R2 = 0.043, p = 0.001, and ∆R2 = 0.027, p = 0.011; and beta: ∆R2 = 0.035, p = 0.005,
and ∆R2 = 0.080, p < 0.0001, respectively). In addition, significant effects were obtained for
theta, and delta frequency bands at electrode positions Fz, Cz, and Pz (theta: ∆R2 = 0.035,
p = 0.001, ∆R2 = 0.029, p = 0.005, and ∆R2 = 0.016, p = 0.047; delta: ∆R2 = 0.051, p < 0.0001,
∆R2 = 0.059, p < 0.0001, and ∆R2 = 0.063, p < 0.0001, respectively). Furthermore, for pre
eyes closed data quality, a significant additional predictive value was obtained for beta,
theta, and delta activity at electrode positions Fz, Cz, and Pz (beta: ∆R2 = 0.026, p = 0.019;
∆R2 = 0.074, p < 0.0001; ∆R2 = 0.081, p < 0.001; theta: ∆R2 = 0.052, p < 0.001; ∆R2 = 0.049,
p < 0.0001; ∆R2 = 0.039, p = 0.002; and delta: ∆R2 = 0.082, p < 0.001; ∆R2 = 0.078, p < 0.0001;
∆R2 = 0.082, p < 0.001). Appendix E (Tables A5–A28) shows full details of the results
obtained from the stepwise multiple regression models.
To explore the association of data quality and spectral power in more detail, post-hoc
correlational analyses were conducted. As revealed by those analyses, data quality is
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negatively correlated with spectral power for all significant results across all different
bands for both conditions, indicating that lower data quality is associated with higher
spectral power.
4. Discussion
4.1. Summary of Results and Interpretation
The first aim of this study was to explore EEG data quality parameters in a multicenter
study of children, adolescents, and adults with ADHD, and a non-ADHD school-age
control sample, and to analyse the potential influence of participant-related and method-
ological variables. Data quality was defined as the percentage of artifact-free segments
in the EEG after pre-processing. The current study found that across assessments, and
most of the measurement conditions, the percentage of artifact-free segments was related
to age, and symptoms of hyperactivity/impulsivity. Age is positively associated with data
quality, indicating higher data quality with increasing age. For symptoms of hyperactiv-
ity/impulsivity, a negative association was obtained, pointing out that with increasing
symptoms of hyperactivity/impulsivity the percentage of artifact-free segments decreases.
For eyes open data, the association between EEG data quality and ADHD symptoms of
hyperactivity/impulsivity was even stronger than for age, whereas for the eyes closed
and CPT conditions effects were comparable for those participant-related characteristics.
This might possibly be due to sequence effects, with increasing time since the start of the
first measurement (resting with eyes open), developmental effects becoming more relevant.
Further, for eyes closed data quality, symptoms of inattention seem to play an additional
role, with higher symptoms being related to lower data quality. A possible explanation
might be that attentional processes are more involved in successfully accomplishing the
task of resting with eyes holding closed (e.g., not to move, not to fall asleep). In addi-
tion, it is important to note that there are substantial age effects across all task conditions
that do not differ between rest conditions and the CPT, even though a more demanding
Flanker-version of the CPT was used for adolescents and adults. Rather than representing
a challenge due to task-inherent demands, the 11 min of task completion for the CPT might
have caused boredom in children contributing to the reported effect. No significant effect
was obtained for condition or any of the methodological influence variables of interest
explored within the current trial. No significant data quality differences were obtained
for the direct comparison of the three conditions (eyes open versus eyes closed versus
CPT, always applied in the same order) across all participants assessed. This indicates that
neither task demands nor time effects seem to have a substantial impact on data quality
across all participants. From these results it can be suggested that whereas participant-
related characteristics have a strong impact on data quality, the methodological differences
regarding study design explored here play a minor role for reliability of EEG study results.
A further objective of this study was to replicate landmark effects typically reported
in the EEG literature to prove validity of data. Effects from maturational processes, task
demands, and ADHD status have been explored. In line with previous findings, the
results of these analyses show that age is negatively associated with EEG spectral power:
With increasing age EEG power decreases, especially for slow oscillatory activity activity
(theta and delta bands). However, correlations found here are a bit lower than reported
previously [24]. This is probably due to a different age range of the assessed ADHD-
study population, and symptoms of ADHD with ADHD-patients typically showing lower
associations. Furthermore, comparing the alpha reactivity between eyes open and eyes
closed conditions, we found an increase in alpha activity in the transition from eyes open
to eyes closed replicating previous robust findings on the alpha blocking phenomenon.
Additionally, validity analyses addressing robust CPT-effects showed a significantly higher
Go-P3 amplitude compared to the NoGo-P3 at posterior regions replicating previous
findings on task manipulation effects. Finally, in line with a recent meta-analysis [32] we
found a significant difference in the Cue-P3 amplitude component between children with
ADHD and non-ADHD controls, with higher amplitudes in control participants. However,
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no significant differences were obtained for other ERP components possibly due to different
developmental effects. By replicating those landmark effects, we can infer substantial
validity of current data allowing for subsequent analyses and valid interpretations, and
further, established a link between data quality and replication of previous study results.
Finally, this study aimed to determine the additional effects of data quality on FFT
spectral power beyond maturational effects and effects due to symptom severity. As indi-
cated by the stepwise regression models, data quality has a relevant additional impact on
spectral power for eyes open, and eyes closed data. As shown by post-hoc correlational
analyses, the associations between data quality and FFT spectral power are negative indi-
cating higher activity in frequency band power with lower data quality. For alpha and beta
frequency bands in eyes open datasets, this result might be explained by the fact that those
bands include the highest frequency band widths ranging from 7.5 to 12.5 Hz and 12.5 to
30 Hz, respectively. These higher frequency band ranges might be more affected by myo-
genic activity near the head with a high-frequency activity of >20 Hz [33]. This increased
myogenic activity might consequently lead to a lower percentage of artifact-free segments
influencing results obtained in FFT analyses, such as diluting or mimicking EEG alpha or
beta rhythms.
4.2. Relevance of Results and Practical Implications
The findings of the current study highlight the relevance of explicit data quality
assessments in EEG studies, especially when younger populations are in the focus of
interest, and when psychiatric samples are explored prone to EEG artifacts. It is interesting
to note, that while participant-related characteristics have a substantial impact on data
quality, reliability, and consequently the interpretability of findings, the methodological
variables explored here have not. This finding has a highly important impact on the process
of study implementation including the planning of data pre-processing strategies. It seems
especially relevant that demographic and clinical characteristics of participant samples
included in studies are reported explicitly in publications: Effects can be classified more
accurately, and addressed in replication studies as well as in reviews and meta-analytic
approaches. Nevertheless, future studies should assess further different methodological
variables, and efforts on methodological standardization for a higher comparability of
study results should moreover be strengthened [43,44].
By replicating robust landmark effects of the EEG literature, we were able to prove
validity of current datasets, and to ensure valid conclusions drawn from subsequent
analyses. Ensuring reliability and validity of assessed data has substantial implications
for the status quo of a research field. They allow for valid interpretation of study results,
and a higher application value, e.g., for deep-learning approaches [45]. This finding
further highlights that large-scale multicenter studies on ADHD patients prone to EEG
artifacts are feasible. This feasibility is urgently needed for further detailed explorations
of the diagnostic and predictive value of EEG/ERP markers for this highly prevalent
neurodevelopmental disorder.
The finding of an additional effect of our data quality index on FFT spectral power
beyond maturational processes and symptoms of ADHD points out to the need for dis-
cussing and challenging EEG results on spectral power as dependent variable, especially
for classification purpose. This result might be due to myogenic activity as a potential
confounder (diluting or mimicking spectral power effects) contaminating the EEG sig-
nal. Nevertheless, those indices might be of value for characterizing psychiatric patients,
especially, when motor activity represents a central characteristic of clinical populations
explored. They might be of additional value for classification purposes and for differ-
entiating clinical from non-clinical groups, as well as between different clinical groups.
In addition, controlling for EEG data quality seems to be urgently needed when spectral
power analyses are conducted.
Brain Sci. 2021, 11, 214 15 of 36
4.3. Limitations and Future Directions
A few limitations of the current work have to be mentioned. First, in our ADHD
sample age was restricted from 6 to 45 years. No older adults were included, and only a few
datasets for adolescents. Therefore, effects are primarily driven by data from children and
young adults. This has to be taken into account when interpreting current results. Future
studies are needed including a sample with a larger age range of included ADHD patients.
Furthermore, only a small non-ADHD sample in school-age was recruited. Therefore, as
we not have a full-factorial design of ADHD status across all age groups, patient-control
comparisons in our validation analyses could only be conducted on children between 6 and
12 years of age. In future work, larger non-ADHD samples should be included spanning a
broader age range.
Within the current study, the focus was set on a few potentially relevant participant-
related and methodological variables influencing data quality. Besides those variables
addressed within the current work, others might be relevant. Further studies are needed at
this stage. In addition, the percentage of artifact-free segments was defined as the relevant
index of data quality. There exist many more data quality indices and further replication of
current results is needed comparing different data quality indices. Within our analyses,
no corrections for multiple testing were applied. However, as our analyses involved
replications, and only partial overlap regarding characteristics and datasets within separate
tests, this is not necessarily recommended.
Additionally, further EEG measures besides spectral power and ERP amplitudes and
latencies might be of relevance for future work on data quality. For example, functional
connectivity measures between different electrode locations could be assessed and an-
alyzed in multivariate models in future studies as they might be relevant for a further
characterization of ADHD. As we are explicitly interested in data quality effects, the current
work focused on peak amplitudes rather than mean amplitudes as peak amplitudes are
typically most affected by noise [46–50]. However, future work will also assess other ERP
indices. In particular, besides peak amplitude data mean amplitudes of relevant ERP
indices will be taken into account for a more robust and unbiased approach.
5. Conclusions
The current study contributes to our understanding of EEG data quality, participant-
related and methodological variables influencing EEG data quality, and the additional
effects of data quality on results obtained from FFT analyses beyond demographic and
clinical characteristics. To the best of our knowledge, this is the first study explicitly
investigating the impact of several study-specific variables on data quality in a large ADHD
sample from 6 to 45 years of age. The results of this investigation show that on the one
hand demographic variables, especially, age and symptoms of hyperactivity/impulsivity,
have a substantial impact on data quality. On the other hand, methodological differences
regarding study-design and analytical methods assessed here have not. Furthermore, the
current work highlights the importance of replication analyses to prove validity of the
assessed data. Additionally, we found that data quality substantially affects spectral power
beyond patient-related characteristics pointing out to the need for cautious interpretations
of results obtained in EEG analyses on frequency band power. These findings have a high
relevance for the implementation of studies, analyzing and publishing EEG data, and for
interpreting scientific results obtained from EEG studies. Further, current results show
that with a careful design and systematic data quality control, informative large-scale
multicenter trials on neurophysiological mechanisms in neurodevelopmental disorders
across the lifespan are actually feasible. Nevertheless, results are restricted to the limitations
discussed. Future studies are needed to replicate and extend current findings.
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Appendix A
Appendix A.1. Assessment of Demographic Information, and Clinical Characterization
Depending on age group and subtrial, the following assessment methods were im-
plemented: for ESCAschool (6;0–11;11 years of age): the clinical interview “Diagnose-
Checkliste für Aufmerksamkeitsdefizit−/Hyperaktivitätsstörungen” (DCL-ADHS; Döpfner
& Görtz-Dorten, 2017), the “Clinical Global Impression Scale–Severity” (CGI-S; National
Institute of Mental Health, 1976), FBB-ADHS-Parent/-Teacher, FBB-SSV-Parent/-Teacher,
SDQ-Parent; for ESCAadol (12;0–17;11 years of age): DCL-ADHS-clinical interview, CGI-S,
SBB-ADHS, FBB-ADHS-Parent/-Teacher, SBB-SSV, FBB-SSV-Parent/-Teacher, SDQ-Parent;
and for ESCAlate (16;0–44;11 years of age): ADHD-DCQ, IDA interview.
Appendix A.2. EEG Data Acquisition—The Continuous Performance (CPT) Task
The cued Continuous Performance Task (CPT-OX/Flanker CPT-OX) was used to
probe attention, preparation, and inhibitory activity at pre- (T2) and post-assessment (T3).
In ESCAschool, the simple version of the cued CPT was used. For participants in the
ESCAadol, and ESCAlate trials, the Flanker-version of the cued CPT was implemented.
The task consists of 400 black letters or letter arrays (for the Flanker-version), made up of
a central black letter (and for the Flanker version: Plus additional incompatible flankers
on each side to increase difficulty). The presented letters or arrays include the cue letter
‘O’, the target letter ‘X’ as well as further distractors (‘H’, ‘B’, ‘C’, ‘D’, ‘E’, ‘F’, ‘G’, ‘J’,
and ‘L’). For the Flanker version of the task in the ESCAadol, and ESCAlate trials, the
cue and target letters (‘O’ and ‘X’, respectively) were flanked by distractor letters (‘XOX’
and ‘OXO’, respectively). Letters were presented every 1.650 ms for 150 ms in a pseudo-
randomized order. Participants were instructed to respond as quickly as possible to cue-
target sequences (‘O’–‘X’). 80 cues were followed by the target in 40 trials (Go condition),
and by neutral distractors in the other 40 trials (NoGo condition). One minute of practice
trials was implemented before the main task and repeated, if required, to ensure participant
understanding of the task. Participants were instructed to respond to Cue-Go trials by
pressing a button as quickly as possible with the index finger of their preferred hand. Task
duration was approximately 11 min.
Appendix B
Data Quality—Effects of Demographic Variables
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Figure A1. Association between age and data quality for all conditions at pre-assessment, respectively.
Figure A2. Association between ADHD symptoms of inattention and data quality for all conditions at pre-assessment, re-
spectively.
Figure A3. Association between ADHD symptoms of hyperactivity/impulsivity and data quality for all conditions at
pre-assessment, respectively.
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Figure A4. Differences in data quality for medication status at pre-assessment, respectively.
Appendix C
Appendix C.1. Data Quality—Effects of Methodological Variables
Appendix C.1.1. Effects of Pre-Processing/Ocular Correction Method
Table A1. Descriptive statistics: Effects of pre-processing/Ocular correction method (ICA versus
Gratton and Coles)—non-ADHD controls only.





Eyes open Gratton and Coles 24 75.85% 25.42%
ICA 24 73.37% 27.32%
Eyes closed Gratton and Coles 25 76.52% 25.54%
ICA 25 75.80% 26.49%
Appendix C.1.2. Effects of Measurement Duration






Eyes open Segment 1 251 75.55 54.19
Segment 2 222 80.43 55.75
Eyes closed Segment 1 247 76.49 56.13
Segment 2 216 79.85 58.26
Appendix C.1.3. Effects of Site
General linear models were used to explore effects of site on data quality for eyes open,
eyes closed, and the CPT task-condition, respectively. Significant effects were identified
for all conditions: Eyes open, F(15,251) = 3.2219, p < 0.0001, eyes closed, F(15,247) = 4.2029,
p < 0.0001, and the CPT, F(13,251) = 4.9926, p < 0.0001. However, as the study sites did
not include participants for all age trials, site represents a confounded variable, and was
therefore not included in subsequent analyses.
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Appendix D
Associations between Age and EEG Spectral Power in Resting Conditions (Eyes Open, and Eyes
Closed) at Pre-Assessment
Figure A5. Association between age and spectral power in beta (A), alpha (B), theta (C), and delta (D) frequency bands for
eyes open data at electrode position Fz.
Figure A6. Association between age and spectral power in beta (A), alpha (B), theta (C), and delta (D) frequency bands for
eyes open data at electrode position Cz.
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Figure A7. Association between age and spectral power in beta (A), alpha (B), theta (C), and delta (D) frequency bands for
eyes open data at electrode position Pz.
Figure A8. Association between age and spectral power in beta (A), alpha (B), theta (C), and delta (D) frequency bands for
eyes closed data at electrode position Fz.
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Figure A9. Association between age and spectral power in beta (A), alpha (B), theta (C), and delta (D) frequency bands for
eyes closed data at electrode position Cz.
Figure A10. Association between age and spectral power in beta (A), alpha (B), theta (C), and delta (D) frequency bands for
eyes closed data at electrode position Pz.
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Table A3. Correlations between age and FFT frequency band activity at pre assessment—non-ADHD <16 years (n = 25).
Eyes Open Eyes Closed
Electrode Location Fz Cz Pz Fz Cz Pz
Beta (µV) × age (years) −0.609 ** −0.456 * −0.475 * −0.492 * −0.415 * −0.330
alpha (µV) × age (years) −0.410 * −0.335 −0.276 −0.201 −0.189 −0.366
theta (µV) × age (years) −0.478 * −0.249 −0.449 * −0.467 * −0.111 −0.409 *
delta (µV) × age (years) −0.566 ** −0.414 * −0.548 ** −0.543 ** −0.373 −0.508 **
Frequency band widths: Beta (12.5–30 Hz), alpha (7.5–12.5 Hz), theta (3.5–7.5 Hz), and delta (0.5–3.5 Hz). Pearson product-moment
correlations are displayed. ** p ≤ 0.001, * p ≤ 0.01.
Table A4. Correlations between age and FFT frequency band activity at pre assessment—ADHD <16 years (n = 150).
Eyes Open Eyes Closed
Electrode Location Fz Cz Pz Fz Cz Pz
beta (µV) × age (years) 0.093 0.044 −0.006 −0.075 −0.108 −0.108
alpha (µV) × age (years) −0.038 −0.122 −0.000 −0.091 −0.163 −0.236 **
theta (µV) × age (years) −0.260 ** −0.276 ** −0.240 ** −0.491 ** −0.476 ** −0.353 **
delta (µV) × age (years) −0.126 −0.232 ** −0.243 ** −0.289 ** −0.381 ** −0.202 *
Frequency band widths: beta (12.5–30 Hz), alpha (7.5–12.5 Hz), theta (3.5–7.5 Hz), and delta (0.5–3.5 Hz). Pearson product-moment
correlations are displayed. ** p ≤ 0.001, * p ≤ 0.01.
Figure A11. Association between age and spectral power in beta (A), alpha (B), theta (C), and delta
(D) frequency bands for eyes open data at electrode position Fz for ADHD (blue) and non-ADHD
(green) children and adolescents <16 years of age.
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Figure A12. Association between age and spectral power in beta (A), alpha (B), theta (C), and delta (D) frequency bands for
eyes open data at electrode position Cz for ADHD (blue) and non-ADHD (green) children and adolescents <16 years of age.
Figure A13. Association between age and spectral power in beta (A), alpha (B), theta (C), and delta (D) frequency bands for
eyes open data at electrode position Pz for ADHD (blue) and non-ADHD (green) children and adolescents <16 years of age.
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Figure A14. Association between age and spectral power in beta (A), alpha (B), theta (C), and delta (D) frequency bands for
eyes closed data at electrode position Fz for ADHD (blue) and non-ADHD (green) children and adolescents <16 years of age.
Figure A15. Association between age and spectral power in beta (A), alpha (B), theta (C), and delta (D) frequency bands for
eyes closed data at electrode position Cz for ADHD (blue) and non-ADHD (green) children and adolescents <16 years of age.
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Figure A16. Association between age and spectral power in beta (A), alpha (B), theta (C), and delta (D) frequency bands for
eyes closed data at electrode position Pz for ADHD (blue) and non-ADHD (green) children and adolescents <16 years of age.
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0.152 0.043 9.66 <0.0001
N = 220. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.135 0.027 8.46 <0.0001
N = 220. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.057 0.015 3.25 0.013
N = 220. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.083 0.035 4.88 0.001
N = 220. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.099 0.080 5.93 <0.0001
N = 220. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.034 0.015 1.89 0.114
N = 220. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.274 0.035 20.43 <0.0001
N = 220. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.243 0.029 17.36 <0.0001
N = 220. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.135 0.016 8.42 <0.0001
N = 220. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.





Step Predictor B SE β p R2 ∆R2 F p









































0.233 0.051 16.13 <0.0001
N = 217. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.233 0.059 16.34 <0.0001
N = 219. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.236 0.063 16.64 <0.0001
N = 220. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.075 0.011 4.15 0.003
N = 208. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.120 0.012 6.97 <0.0001
N = 208. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.090 0.005 5.03 0.001
N = 208. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.063 0.026 3.41 0.010
N = 208. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.102 0.074 5.77 <0.0001
N = 208. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.128 0.081 7.46 <0.0001
N = 208. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.325 0.052 24.52 <0.0001
N = 208. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.273 0.049 19.15 <0.0001
N = 208. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.





Step Predictor B SE β p R2 ∆R2 F p









































0.191 0.039 12.07 <0.0001
N = 208. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.247 0.082 16.66 <0.0001
N = 207. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.285 0.078 20.21 <0.0001
N = 207. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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0.229 0.082 15.12 <0.0001
N = 208. Hyp/imp = Hyperactivity/impulsivity. SE = standard error of B.
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